<DOC>
	<DOCNO>NCT00730561</DOCNO>
	<brief_summary>Several pathophysiological theory propose development diabetic chronic complication . In recent year , use stem cell ( totipotential , hematopoietic endothelial lineage ) report adjunctive modality treatment ischemia model animal human . Nevertheless , report use stem cell treatment human sensorimotor peripheral diabetic neuropathy . We perform study evaluate effect autologous hematopoietic CD34+ cell transplantation nerve conduction velocity patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplantation Treatment Limb Ischemia Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Ambulatory patient type 2 diabetes mellitus ischemia one low limb , define lack limb improvement conventional care ( medication , debridement ) recent amputation patient grade III IV LericheFontaine functional classification . Patients older 75 year Hypercoagulable state Cardiac ejection fraction &lt; 30 % Active vasculopathy brain , kidneys heart Neoplastic disease Active infection Diabetic ketoacidosis hyperosmolar hyperglycemic state Gangrene extremity require immediate surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>nerve conduction velocity</keyword>
	<keyword>hematopoietic stem cell transplantation</keyword>
</DOC>